文献速递白血病MDS 与骨髓增殖性肿瘤

BRAF突变在急性髓系白血病中的预后与治疗意义

Prognostic and therapeutic implications of BRAF mutations in acute myeloid leukemia.
PubMed 文献 · Leukemia · 2026-06-15

该研究在5779例连续且临床与分子注释完整的AML患者中鉴定出约1%的BRAF突变(50/5779),其中21例新诊断、9例复发/难治、20例新诊断继发性AML。BRAF突变富集于骨髓增生异常相关AML(AML-MR),多数位于V600热区之外,单细胞多组学揭示突变类别特异的共突变、克隆性和免疫表型模式,且BRAF突变可与其它信号共突变共存于同一细胞。BRAF突变患者在当前可用治疗(包括维奈克拉方案)下总生存差,药敏数据提示潜在靶向治疗途径。

要点

  • BRAF突变在AML中约占1%,富集于骨髓增生异常相关AML(AML-MR)。
  • 多数BRAF突变位于V600热区之外,且可与其它信号共突变共存于同一细胞。
  • BRAF突变患者当前治疗(含维奈克拉方案)下总生存差,药敏提示靶向治疗可能。

核心结论

  • BRAF突变AML约占1%,富集于AML-MR,多数非V600突变,当前治疗下总生存差,药敏提示潜在靶向治疗途径。

研究设计与样本

  • 在美国两家主要癌症中心连续纳入5779例临床与分子注释完整的AML患者,鉴定出50例BRAF突变(21例新诊断、9例复发/难治、20例新诊断继发性AML)。
  • 对部分AML样本进行单细胞多组学分析。

主要发现

  • BRAF突变富集于骨髓增生异常相关AML(AML-MR),多数突变位于V600热区之外。
  • 单细胞多组学揭示BRAF突变类别特异的共突变、克隆性和免疫表型模式。
  • BRAF突变可与其它信号共突变共存于同一细胞,显著不同于既往RAS突变AML研究。
  • BRAF突变AML患者在当前可用治疗(包括维奈克拉方案)下总生存差。

临床怎么用

  • 对AML患者(尤其AML-MR)应关注BRAF突变检测,非V600突变亦需覆盖。
  • BRAF突变AML预后差,当前含维奈克拉方案疗效不佳,可参考药敏数据探索靶向治疗。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Mutations in the RAS/MAPK signaling pathway are recurrent in acute myeloid leukemia (AML), primarily involving NRAS and KRAS. In contrast, mutations in the gene encoding an effector protein, BRAF, occur at relatively lower frequencies in AML and are associated with poor outcomes. To date, no comprehensive analysis has assessed the clinical and molecular characteristics of BRAF-mutated AML. In this study, we report the identification of canonical and non-canonical BRAF mutations in ~1% of 5779 consecutive clinically and molecularly fully annotated AML patients treated at two major United States Cancer Centers (50/5779 AML patients: 21 newly diagnosed AML; 9 relapsed/refractory; 20 newly diagnosed secondary AML). We performed single-cell multiomic analysis on a subset of AML samples. BRAF mutations were enriched in myelodysplasia-related AML (AML-MR), and most mutations were located outside the V600 hotspot. Single-cell multiomic profiling delineated BRAF mutation class-specific patterns of co-mutations, clonality, and immunophenotypes. Notably, BRAF mutations and other signaling co-mutation(s) could be found in the same cell, a finding that significantly diverges from prior studies of RAS-mutant AML. In this cohort, BRAF-mutant AML patients had poor overall survival with currently available treatments, including venetoclax-based regimens. Drug sensitivity data suggest possible avenues for targeted treatment of BRAF-mutated AML.

来源:Leukemia,查看原文。版权归原作者所有。

引用

  1. Lee D, Abu-Shihab Y, Plas K, et al. Prognostic and therapeutic implications of BRAF mutations in acute myeloid leukemia. Leukemia. 2026. PMID: 42297916. doi:10.1038/s41375-026-02996-1

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。